Table 2. Antibacterial Virulence of the High-Activity Compounds against Xoo and Aac.

bacteria	compound	LC-P	r	EC50 (μg/mL)	95%FL (μg/mL)
Xoo	A1	2.85 + 1.71x	0.96	18.12	12.68–25.89
	A7	2.58 + 1.98x	0.95	16.7	11.98–23.30
	A9	3.42 + 1.52x	0.97	11.05	7.03–17.36
	A10	2.06 + 2.79x	0.96	11.26	9.13–13.88
	A11	2.58 + 2.03x	0.99	15.55	11.20–21.58
	A12	2.48 + 1.72x	0.98	29.09	20.84–40.59
	A13	3.59 + 1.17x	0.99	16.34	10.73–24.87
	A23	1.90 + 2.36x	0.98	20.72	15.84–27.09
	A27	2.26 + 2.03x	0.97	22.42	16.65–30.19
	A29	2.62 + 1.65x	0.97	27.91	19.69–39.55
	A35	3.29 + 1.46	0.99	14.87	10.51–21.05
	A38	2.73 + 1.76x	0.99	19.42	13.81–27.30
	3-CCA	2.58 + 1.63x	0.97	30.37	21.27–43.37
	kasugamycin	3.76 + 1.16x	0.99	11.65	6.95–19.53
Aac	A1	1.45 + 2.34x	0.97	32.65	25.15–42.38
	A9	3.42 + 1.74x	0.99	8.05	5.75–11.27
	A11	2.99 + 1.38x	0.99	28.15	18.86–42.01
	A13	2.87 + 1.52x	0.98	24.95	17.59–35.40
	A17	3.12 + 1.43x	0.98	20.71	13.88–30.89
	A35	2.79 + 1.86x	0.99	15.42	11.63–20.45
	3-CCA	3.23 + 1.1x	0.98	39.48	24.51–63.58
	kasugamycin	3.45 + 1.37x	0.97	13.55	8.81–20.83